Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 1096-1099

  Quan, Hua ^a   Cao, Ying Ying ^a   Xu, Zheng ^a   Zhao, Jing Xia ^a   Gao, Ping Hui ^a   Qin, Xiao Feng ^a   Jiang, Yuan Ying ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Changhai Hospital of Second Military Medical University ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; FLUCONAZOLE;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; DILUTION; DRUG ANTAGONISM; DRUG CROSS REACTIVITY; DRUG POTENCY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BERBERINE; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33644650719     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.1096-1099.2006     Document Type: Article

References (29)

1. Barchiesi, F., L. Falconi Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
2. Boken, D. J., S. Swindells, and M. G. Rinaldi. 1993. Fluconazole- resistant Candida albicans. Clin. Infect. Dis. 17:1018-1021.
3. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):S318-S326.
4. D'Auria, F. D., M. Tecca, R. Strippoli, and N. Simonetti. 2001. In vitro activity of propyl gallate-azole drug combination against fluconazole- and itraconazole-resistant Candida albicans strains. Lett. Appl. Microbiol. 32:220-223.
5. Edwards, J. E., Jr., G. P. Bodey, R. A. Bowden, T. Buchner, B. E. de Pauw, S. G. Filler, M. A. Ghannoum, M. Glauser, R. Herbrecht, C. A. Kauffman, S. Kohno, P. Martino, F. Meunier, T. Mori, M. A. Pfaller, J. H. Rex, T. R. Rogers, R. H. Rubin, J. Solomkin, C. Viscoli, T. J. Walsh, and M. White. 1997. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25:43-59.
6. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
7. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511.
8. Gil-Lamaignere, C., and F. M. Muller. 2004. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int. J. Antimicrob. Agents 23:520-523.
9. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
10. Han, Y., and J. H. Lee. 2005. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol. Pharm. Bull. 28:541-544.
11. Henry, K. W., M. C. Cruz, S. K. Katiyar, and T. D. Edlind. 1999. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob. Agents Chemother. 43:1968-1974.
12. Kelly, S. L., A. Arnoldi, and D. E. Kelly. 1993. Molecular genetic analysis of azole antifungal mode of action. Biochem. Soc. Trans. 21:1034-1038.
13. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
14. Lewis, R. E., and D. P. Kontoyiannis 2001. Rationale for combination antifungal therapy. Pharmacotherapy 21:1498-1648.
15. Lupetti, A., R. Danesi, M. Campa, M. Del Tacca, and S. Kelly. 2002. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 8:76-81.
16. Marchetti, O., P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44:2373-2381.
17. Nakamoto, K., S. Sadamori, and T. Hamada. 1990. Effects of crude drugs and berberine hydrochloride on the activities of fungi. J. Prosthet. Dent. 64:691-694.
18. National Committee for Clinical and Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts, vol. 17, no. 9. Approved standard M27-A. National Committee for Clinical and Laboratory Standards, Wayne. Pa.
19. Ng, T. T., and D. W. Denning. 1993. Fluconazole resistance in Candida in patients with AIDS-a therapeutic approach. J. Infect. 26:117-125.
20. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
21. Park, K. S., K. C. Kang, J. H. Kim, D. J. Adams, T. N. Johng, and Y. K. Paik. 1999. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in Candida albicans. J. Antimicrob. Chemother. 43:667-674.
22. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
23. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
24. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
25. Sasaki, E., S. Maesaki, Y. Miyazaki, K. Yanagihara, K. Tomono, T. Tashiro, and S. Kohno. 2000. Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. J. Infect. Chemother. 6:151-154.
26. Vollekova, A., D. Kost'alova, V. Kettmann, and J. Toth. 2003. Antifungal activity of Mahonia aquifolium extract and its major protoberberine alkaloids. Phytother. Res. 17:834-837.
27. Weig, M., and F. M. Muller. 2001. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 45:966-968.
28. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
29. Wilson, L. S., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.